Efficacy of acalabrutinib. (A) The rate of overall response, including complete remission and partial remission, in the BID group and the QD group. (B) Absolute lymphocyte count during treatment. (C) Maximum percent change in the sum of the product of dimensions during treatment. (D) Quantification of disease burden in bone marrow and peripheral blood separated by dosing groups. Line denotes median of each group at the indicated time point. *P < .05. NED, no evidence of disease.